Furthermore, several other mutations leading to increased PI3K/AKT pathway signaling (i.e., TIE2, PTEN, AKT) are also linked to vascular anomalies and overgrowth syndromes [47], providing evidence that AKT is a potential common therapeutic target for the treatment of these anomalies. The gene discussed is TEK; the disease is overgrowth syndrome.